[2-[(3-Chlorophenyl)carbamoylimino]-5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-3-yl]methyl 2-methylpropanoate | 1146618-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: [2-[(3-Chlorophenyl)carbamoylimino]-5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-3-yl]methyl 2-methylpropanoate
• CAS: 1146618-39-4
• 化学式: C₂₃H₂₃ClN₆O₃S₂
• 分子量: 531.059
• InChiKey: KIJOYVQOIWEHRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.15
• 重原子数：
  35.0
• 可旋转键数：
  8.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  110.5
• 氢给体数：
  2.0
• 氢受体数：
  9.0

反应信息

• 作为产物：
  描述：

  N-(3-氯苯基)-N’-[5-[2-(噻吩并[3,2-d]嘧啶-4-基氨基)乙基]-2-噻唑基]脲 、 氯甲基异酪酸盐 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以13%的产率得到[2-[(3-Chlorophenyl)carbamoylimino]-5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-3-yl]methyl 2-methylpropanoate
  参考文献：
  名称：

  Water-soluble prodrugs of an Aurora kinase inhibitor

  摘要：

  Compound 1 (SNS-314) is a potent and selective Aurora kinase inhibitor that is currently in clinical trials in patients with advanced solid tumors. This communication describes the synthesis of prodrug derivatives of 1 with improved aqueous solubility profiles. In particular, phosphonooxymethyl-derived prodrug 2g has significantly enhanced solubility and is converted to the biologically active parent (1) following iv as well as po administration to rodents. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.043